The sector will reach USD 223.885 billion by 2027 at 7.99% CAGR

DUBLIN, January 24, 2023 /PRNewswire/ — The Monoclonal Antibody Market – Forecast 2022 to 2027 report has been added to ResearchAndMarkets.com supply.

Research and Markets Logo

The monoclonal antibody market is projected to grow by a CAGR of 7.99% to reach 223.885 billion US dollars until 2027, from 130.758 billion US dollars in 2020

The immune system naturally produces antibodies in response to infection. A monoclonal antibody is a molecule designed to boost the body’s immune system’s natural response to an invader, such as cancer or infection. It is developed in a laboratory and therefore falls under the group of man-made drugs.

Monoclonal antibodies are designed to specifically target an essential part of the infection process and therefore have an advantage over other types of infection treatment. It is created by exposing white blood cells to a certain viral protein. It is then cloned to mass produce antibodies targeting this virus.

Monoclonal antibodies have been developed to treat several viral infections, such as Ebola and rabies. They were widely used during the COVID-19 pandemic because clinical trials proved the antibodies to be effective in reducing the severity of symptoms.

Increased demand for monoclonal antibodies

According to the World Health Organization, about 10 million people died of cancer worldwide in 2020. For the treatment of cancer, monoclonal antibodies are significantly useful, hence there is a growing need for affordable cancer therapies. In addition, during the COVID-19 pandemic, a large number of clinical trials of monoclonal antibodies were conducted to develop new drug therapy, as well as a wide range of product approvals for emergency use in the treatment of COVID-19.

With increasing demand, market players have a strong focus on development as well as discovery of monoclonal antibody therapeutics. A step has been taken towards offering highly specific treatment for complex and severe diseases. Furthermore, this will boost the growth potential of the monoclonal antibody market.

Key developments

  • in April 2020, Merck announced the launch of a biosimilar to trastuzumab (Herceptin), which is widely recommended for the treatment of metastatic breast cancer and metastatic gastric cancer. The biosimilar trastuzumab is known as trastuzumab-dttb (Ontruzant), c United States. Doses are available in both 150 mg single-dose vials and 420 mg multiple-dose vials. in January 2019, FDA approved Trastuzumab-dttb. In addition, in March 2020, the FDA subsequently approved 420-mg multidose trastuzumab-bttb. The US launch was made as part of a development and commercialization agreement with Samsung Bioepis.

  • in May 2022Swiss multinational Roche Pharma announced the launch of the world’s first fixed-dose combination of two monoclonal antibodies, PHESGO, in oncology for the treatment of HER-2-positive breast cancer in India. The company combines the injections Perjeta (pertuzumab) and Herceptin (trastuzumab). The dose will be used as intravenous (IV) chemotherapy. They will be useful in the treatment of early and metastatic HER2-positive breast cancer. The dosage combination is approved in over 100 countries worldwide. The company has listed the price of the drug as 20% lower than individual meditations.

  • in February 2019, China’s National Medical Products Administration (NMPA) approved Henlius’ first product, HLX01 (rituximab injection). The dose will be used to treat adult patients in three indications as- i) relapsed or refractory, follicular lymphoma, ii) previously untreated follicular stage III-IV, non-Hodgkin’s lymphoma and iii) CD20-positive. The HLX01 was of China the first approved product that was the first independently researched and developed mAb drug in China.

North America is expected to hold a significant share during the expected period

North American countries have a well-developed health infrastructure. However, the high alcohol intake and junk/fast food culture in this region leads to obesity and also puts the population at high risk of contracting cancer. According to a study by American Cancer Society researchers in 2019, at least 42 percent of newly diagnosed cancers in the U.S. — about 740,000 cases in 2019 — were potentially avoidable. The study also said that of newly diagnosed cancer patients, 19% of all cancers were caused by smoking, and 18% were caused by lack of physical activity, excessive alcohol and junk food consumption, leading to overweight and poor nutrition . In addition, new vaccines/drugs are being developed to help treat cancer patients.

Market Segmentation:

By testimony

  • Inflammatory disease

  • Crab

  • Microbial disease

  • others

By source

  • Humanized

  • Person

  • Chimeric

  • Mouse

Through an app

  • Diagnosis

  • Therapeutic

  • others

By end user

  • Hospitals and clinics

  • Research laboratories

At Geography

  • North America

  • USA

  • Canada

  • Mexico

  • South America

  • Brazil

  • Argentina

  • others

  • Europe

  • Germany

  • France

  • Great Britain

  • Spain

  • others

  • Middle East and Africa

  • Saudi Arabia

  • UAE

  • others

  • Asia and the Pacific

  • China

  • Japan

  • South Korea

  • India

  • Thailand

  • Taiwan

  • others

Main topics covered:

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. SUMMARY

4. MARKET DYNAMICS

5. MONOCLONAL ANTIBODIES MARKET BY INDICATION

6. MONOCLONAL ANTIBODIES MARKET BY SOURCES

7. MONOCLONAL ANTIBODIES MARKET, BYApplication

8. MONOCLONAL ANTIBODIES MARKET BY END USER

9. MONOCLONAL ANTIBODIES MARKET BY GEOGRAPHY

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

11. COMPANY PROFILES

The mentioned companies

For more information on this report, visit https://www.researchandmarkets.com/r/jm7nqd

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We bring you the latest data on international and regional markets, key industries, leading companies, new products and the latest trends.

Media contact:

Research and Markets
Laura WoodSenior Manager
[email protected]

For EST hours Call +1-917-300-0470
For USA/Canada Call Toll Free +1-800-526-8630
For GMT business hours Call +353-1-416-8900

US Fax: 646-607-1904
Fax (outside USA): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Sission

Sission

See original content: https://www.prnewswire.com/news-releases/monoclonal-antibodies-global-market-report-2022-sector-to-reach-223-885-billion-by-2027-at-a- 7-99-cagr-301729433.html

SOURCE Research and Markets

Leave a Comment

Your email address will not be published. Required fields are marked *